1) Methodological differences (use of anesthesia, stretch methodology, et |
2) s), (b) factors linked to implementation (use of manuals, training of implementers a |
3) Time-use of older adults can be different than |
4) Use of diabetes technology is associated w |
5) Use of information technology could be inc |
6) Use of personal protective equipments and |
7) Use of the method allows the detection of |
8) nce regarding asepsis include the topical use of >0.5% chlorhexidine preparation |
9) This scoping review explored the use of ACT as an intervention to support a |
10) They explored the use of AI in cleft lip and/or palate to ai |
11) tions to contribute to a more responsible use of AI technologies in dentistry. |
12) the body of literature investigating the use of AMF data to predict morbidity and m |
13) mplications for clinical protocols in the use of Botulinum Toxin in children with ce |
14) fulness-based clinical trials allowed the use of CADTs. |
15) d that there is limited literature on the use of DHT to enable remote care in respon |
16) Several studies report on the use of EPAs to evaluate different curricul |
17) d and aphasic language processing and the use of ERPs with PWA. |
18) The use of GLP-1 analog was able to decrease b |
19) ns generally have positive regard for the use of HTN guidelines to achieve HTN treat |
20) ithout genotyping error, complicating the use of HWE testing to assess genotype data |
21) ations provide additional support for the use of MRD as a surrogate end point for PF |
22) recent European Medicines Agency-approved use of MSCs in Crohn-related fistular dise |
23) sponders and quantify how first responder use of N95 respirators and patient use of |
24) Although use of NAMs for higher level regulatory de |
25) ies are required to address the potential use of NC and WrC as predictors of early m |
26) We conclude that the use of NC and WrC, in addition to other we |
27) ed 33 primary articles that described the use of NEPIs. |
28) aims to explore the current evidence for use of NEWS in community settings. |
29) n regarding non-medical and extra-medical use of NSAIDs. |
30) ho engage in non-medical or extra-medical use of NSAIDs; (2) antecedents for non-med |
31) en into consideration when optimizing the use of NTX in the pediatric population. |
32) e decades-old bans on the manufacture and use of PCBs. |
33) Finally, we illustrate the use of PCovR2 by means of empirical data. |
|